209 related articles for article (PubMed ID: 31923801)
61. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
62. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
Luque M; Sanz-Álvarez M; Santamaría A; Zazo S; Cristóbal I; de la Fuente L; Mínguez P; Eroles P; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948097
[TBL] [Abstract][Full Text] [Related]
63. Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.
Keller M; Rohlf K; Glotzbach A; Leonhardt G; Lüke S; Derksen K; Demirci Ö; Göçener D; AlWahsh M; Lambert J; Lindskog C; Schmidt M; Brenner W; Baumann M; Zent E; Zischinsky ML; Hellwig B; Madjar K; Rahnenführer J; Overbeck N; Reinders J; Cadenas C; Hengstler JG; Edlund K; Marchan R
J Exp Clin Cancer Res; 2023 Jan; 42(1):25. PubMed ID: 36670508
[TBL] [Abstract][Full Text] [Related]
64. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
65. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
66. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
[TBL] [Abstract][Full Text] [Related]
67. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
[TBL] [Abstract][Full Text] [Related]
68. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
69. Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
Ikink GJ; Boer M; Bakker ERM; Vendel-Zwaagstra A; Klijn C; Ten Hoeve J; Jonkers J; Wessels LF; Hilkens J
Oncogene; 2018 Mar; 37(12):1594-1609. PubMed ID: 29326437
[TBL] [Abstract][Full Text] [Related]
70. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
[TBL] [Abstract][Full Text] [Related]
71. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.
Shi J; Li F; Yao X; Mou T; Xu Z; Han Z; Chen S; Li W; Yu J; Qi X; Liu H; Li G
Oncogene; 2018 May; 37(22):3022-3038. PubMed ID: 29535422
[TBL] [Abstract][Full Text] [Related]
72. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
[No Abstract] [Full Text] [Related]
73. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
[TBL] [Abstract][Full Text] [Related]
75. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
76. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
77. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
Huang WC; Hung CM; Wei CT; Chen TM; Chien PH; Pan HL; Lin YM; Chen YJ
Oncotarget; 2016 Sep; 7(38):62352-62363. PubMed ID: 27694691
[TBL] [Abstract][Full Text] [Related]
78. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
[TBL] [Abstract][Full Text] [Related]
79. Phf8 loss confers resistance to depression-like and anxiety-like behaviors in mice.
Walsh RM; Shen EY; Bagot RC; Anselmo A; Jiang Y; Javidfar B; Wojtkiewicz GJ; Cloutier J; Chen JW; Sadreyev R; Nestler EJ; Akbarian S; Hochedlinger K
Nat Commun; 2017 May; 8():15142. PubMed ID: 28485378
[TBL] [Abstract][Full Text] [Related]
80. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
